ストックスクリーナーアプリを入手
1.63
7.95%
0.12
前日終値:
$1.51
開ける：
$1.53
24時間の取引高:
32,128
Relative Volume:
0.13
時価総額：
$121.10M
収益：
-
当期純損益:
$-19.57M
株価収益率:
-0.5208
EPS:
-3.13
ネットキャッシュフロー:
$-17.24M
1週間 パフォーマンス:
-9.44%
1か月 パフォーマンス:
-11.89%
6か月 パフォーマンス:
-27.88%
1年 パフォーマンス:
+23.48%
1日の値動き範囲:
$1.53
$1.63
1週間の範囲:
$1.415
$1.78
52週間の値動き範囲:
$1.12
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
名前
Inhibikase Therapeutics Inc
セクター
電話
678-392-3419
住所
3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA
IKT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.629 | 106.31M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
382.75 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.72 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.74 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
643.66 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.57 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-12 | ダウングレード | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc (IKT) 最新ニュース
Automated trading signals detected on Inhibikase Therapeutics Inc.Free Weekly Setup With 3x Return Potential - Newser
Visual analytics tools that track Inhibikase Therapeutics Inc. performanceWealth Accumulation Outlook for Safe Investors - Newser
Key metrics from Inhibikase Therapeutics Inc.’s quarterly dataSwing Watchlist With Tight Stop Placement - Newser
What indicators show strength in Inhibikase Therapeutics Inc.Free Real Market Momentum Signal Generator - Newser
Visual trend scoring systems applied to Inhibikase Therapeutics Inc.Entry Confirmation Using Short-Term Forecasting - Newser
Chart based analysis of Inhibikase Therapeutics Inc. trendsDaily Entry Opportunity Forecasting Tool - Newser
How high can Inhibikase Therapeutics Inc. stock goMonthly Long-Term Market Recap and Summary - Newser
Risk vs reward if holding onto Inhibikase Therapeutics Inc.Tactical Trade Setup With Entry Optimizer - Newser
Using fundamentals and technicals on Inhibikase Therapeutics Inc.Top Stock Picks with Forecast Accuracy - Newser
What risks could impact Inhibikase Therapeutics Inc. stock performanceFree Weekly Potential Breakout Stock List - Newser
Inhibikase Therapeutics Inc. recovery potential after sell offSmart Risk Strategy with Entry Optimization - Newser
How Inhibikase Therapeutics Inc. stock performs during market volatilitySafe Entry Screening with Data Backed Analysis - Newser
Real time pattern detection on Inhibikase Therapeutics Inc. stockChart Driven Opportunity Scanner with Alerts - Newser
Published on: 2025-08-06 00:58:01 - Newser
How institutional ownership impacts Inhibikase Therapeutics Inc. stockPortfolio Allocation Strategy for Stability - Newser
Published on: 2025-08-04 16:30:58 - metal.it
New Product Launches: Will They Boost Inhibikase Therapeutics Inc. Stock in 2025Free AI Driven Buy Alert Trade Blueprint - Newser
What institutional investors are buying Inhibikase Therapeutics Inc. stockMarket-leading capital gains - Jammu Links News
How does Inhibikase Therapeutics Inc. compare to its industry peersOutstanding capital growth - Jammu Links News
Is Inhibikase Therapeutics Inc. stock overvalued or undervaluedFastest return on investment - Jammu Links News
What is the risk reward ratio of investing in Inhibikase Therapeutics Inc. stockConsistent high-performance stocks - Jammu Links News
When is Inhibikase Therapeutics Inc. stock expected to show significant growthBuild a portfolio that outperforms the market - Jammu Links News
What are the latest earnings results for Inhibikase Therapeutics Inc.Unlock powerful investment tools for free - Jammu Links News
Is it the right time to buy Inhibikase Therapeutics Inc. stockDiscover market opportunities with expert help - Jammu Links News
Candlestick signals on Inhibikase Therapeutics Inc. stock todayFree Early Breakout Entry Point Notifications - newser.com
What makes Inhibikase Therapeutics Inc. stock price move sharplyIdentify winners with top-tier analysis - Jammu Links News
What drives Inhibikase Therapeutics Inc. stock priceMaximize gains with data-driven trading alerts - Jammu Links News
What are Inhibikase Therapeutics Inc. company’s key revenue driversStay informed with daily expert analysis - Jammu Links News
Inhibikase Therapeutics (NYSE:IKT) and Genocea Biosciences (NASDAQ:GNCAQ) Head to Head Comparison - Defense World
Published on: 2025-08-01 22:50:53 - Newser
Intraday pattern recognizer results for Inhibikase Therapeutics Inc.ROI Focused Watchlist with Trade Confidence - Newser
Inhibikase Therapeutics Inc (IKT) 財務データ
収益
当期純利益
現金流量
EPS
Inhibikase Therapeutics Inc (IKT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kush Arvind | Director |
Oct 21 '24 |
Buy |
1.37 |
145,000 |
198,650 |
145,000 |
| Munshi Amit | Director |
Oct 21 '24 |
Buy |
1.37 |
365,000 |
500,050 |
365,000 |
0.36%
2.76%
大文字化:
|
ボリューム (24 時間):